Aclaris Therapeutics, Inc. (ACRS)
6.54
+0.23
(+3.65%)
USD |
NASDAQ |
Aug 25, 16:00
6.54
0.00 (0.00%)
After-Hours: 16:08
Aclaris Therapeutics Total Liabilities (Quarterly) : 55.11M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 55.11M |
| March 31, 2026 | 55.07M |
| December 31, 2025 | 57.38M |
| September 30, 2025 | 55.43M |
| June 30, 2025 | 57.41M |
| March 31, 2025 | 54.03M |
| December 31, 2024 | 64.77M |
| September 30, 2024 | 52.24M |
| June 30, 2024 | 27.25M |
| March 31, 2024 | 32.05M |
| December 31, 2023 | 42.37M |
| September 30, 2023 | 62.02M |
| June 30, 2023 | 55.90M |
| March 31, 2023 | 52.90M |
| December 31, 2022 | 60.34M |
| September 30, 2022 | 47.79M |
| June 30, 2022 | 42.22M |
| March 31, 2022 | 46.33M |
| December 31, 2021 | 53.87M |
| September 30, 2021 | 46.91M |
| June 30, 2021 | 54.23M |
| March 31, 2021 | 49.10M |
| Date | Value |
|---|---|
| December 31, 2020 | 33.13M |
| September 30, 2020 | 31.14M |
| June 30, 2020 | 35.63M |
| March 31, 2020 | 38.64M |
| December 31, 2019 | 28.38M |
| September 30, 2019 | 75.14M |
| June 30, 2019 | 80.01M |
| March 31, 2019 | 70.93M |
| December 31, 2018 | 60.44M |
| September 30, 2018 | 29.85M |
| June 30, 2018 | 27.62M |
| March 31, 2018 | 20.15M |
| December 31, 2017 | 20.35M |
| September 30, 2017 | 17.13M |
| June 30, 2017 | 8.664M |
| March 31, 2017 | 5.921M |
| December 31, 2016 | 6.595M |
| September 30, 2016 | 4.949M |
| June 30, 2016 | 5.852M |
| March 31, 2016 | 4.059M |
| December 31, 2015 | 1.555M |
| September 30, 2015 | 1.90M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Corcept Therapeutics, Inc. | 182.93M |
| Nektar Therapeutics | 192.01M |
| Xeris Biopharma Holdings, Inc. | 421.64M |
| Crinetics Pharmaceuticals, Inc. | 129.92M |
| Alumis, Inc. | 108.46M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 179.69M |
| Shareholders Equity (Quarterly) | 124.58M |
| Debt to Equity Ratio | 0.0149 |
| Current Ratio | 3.462 |
| Net Debt Paydown Yield | 0.02% |